MINI FUTURE SHORT - BRISTOL-MYERS SQUIBB | Market Closed - Boerse Frankfurt Warrants 03:20:29 2024-07-11 pm EDT | ||
| 0.82 EUR | +2.50% |
|
| Current month | -1.23% | ||
| 1 month | +17.65% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
| Date | Price | Change |
|---|---|---|
| 24-07-11 | 0.82 | +2.50% |
| 24-07-10 | 0.8 | -2.44% |
| 24-07-09 | 0.82 | -8.89% |
| 24-07-08 | 0.9 | -2.17% |
| 24-07-05 | 0.92 | +2.22% |
Real-time Boerse Frankfurt Warrants
Last update July 11, 2024 at 03:20 pm EDT
More quotesStatic data
| Product type | Warrant Knock-Out con Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
BNP Paribas
|
| WKN | PC82DX |
| ISIN | DE000PC82DX3 |
| Date issued | 2024-04-29 |
| Strike | 49.53 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.47 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.95 € |
|---|---|
| Lowest since issue | 0.43 € |
| Spread | 0.01 € |
| Spread % | 1.22% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
41.12
USD
Average target price
52.92
USD
Spread / Average Target
+28.70%
- Stock Market
- Certificates
- Certificat
